Ocular Therapeutix, Inc. (OCUL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$7.14+4.69%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · OCUL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 70.4% |
| Our one-year growth estimate | diamond | 76.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 6.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
OCUL — CEO transition
Dated 2026-10-16
Chief Strategy Officer — Sanjay Nayak: The Chief Strategy Officer resigned to become CEO of another company, representing a genuine executive departure but with a clear, non-adverse reason.
Why it matters: The filing is the next key test of the FDA-aligned plan. A delay could push back the review and launch path.
Supportive ifOcular submits the AXPAXLI wet AMD NDA in Q4 2026. It uses SOL-1 Week 52 data and interim SOL-R safety data.
Worry ifOcular says the NDA filing has slipped past Q4 2026 or the FDA asks for more data before filing.
Why it matters: Ocular is building its sales team and payer plans before approval. A launch delay could add costs and push out sales.
Supportive ifAfter an FDA decision, Ocular names a 2027 launch date and reports that payer coverage plans are in place.
Worry ifOcular delays its launch plan beyond 2027, or reports that approval or payer access is blocking launch plans.
Why it matters: Ocular is loss-making and expects cash to last into 2028. Faster cash use could raise funding needs before launch.
Worry ifOcular reports that cash has fallen below $598.6 million. It now expects its cash runway to end before 2028.
Less concerning ifOcular keeps its runway into 2028 while funding the listed trials and pre-launch work.
Why it matters: The meeting can show whether the planned filing package and 505(b)(2) path remain on track.
Supportive ifOcular reports that the FDA accepts the planned NDA package, including interim SOL-R safety data. The FDA requests no new study.
Worry ifOcular says the FDA wants more clinical data or a new filing plan after the pre-NDA meeting.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$259 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $676 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,096 loss on $10,000 · 61.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.